SCHEMBL355357

SCHEMBL355357

CSc1ncccc1C(=O)O

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.59
SMN1; SMN2 Q16637 3/20 0.59
GAA P10253 2/20 0.59
RAB9A P51151 2/20 0.59
TSHR P16473 2/20 0.59
L3MBTL1 Q9Y468 2/20 0.59
CASP3 P42574 1/20 0.59
SENP8 Q96LD8 1/20 0.59
SENP7 Q9BQF6 1/20 0.59
SENP6 Q9GZR1 1/20 0.59
CYP2C9 P11712 1/20 0.58
KMT2A Q03164 3/20 0.58
NPC1 O15118 1/20 0.57
KDM4E B2RXH2 2/20 0.57
TDP1 Q9NUW8 1/20 0.57
TP53 P04637 1/20 0.56
PKM P14618 1/20 0.55
CYP3A4 P08684 1/20 0.55
MAPT P10636 1/20 0.55
ALOX15 P16050 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL1375604 0.98 ALDH1A1 (0.62) ALDH1A1SMN1; SMN2GAARAB9ATSHR
SCHEMBL25403374 0.86 KMT2A (0.50) ALDH1A1SMN1; SMN2GAARAB9ATSHR
SCHEMBL8284968 0.85 KMT2A (0.62) ALDH1A1RAB9ATSHRL3MBTL1CASP3
SCHEMBL146157 0.84 ALDH1A1 (0.62) ALDH1A1SMN1; SMN2GAARAB9ATSHR
SCHEMBL934289 0.83 KMT2A (0.56) ALDH1A1GAARAB9ATSHRL3MBTL1
SCHEMBL9313441 0.83 KMT2A (0.56) ALDH1A1RAB9ATSHRL3MBTL1CASP3
SCHEMBL1327237 0.83 KMT2A (0.56) ALDH1A1RAB9ATSHRL3MBTL1CASP3
SCHEMBL3077349 0.83 KMT2A (0.56) ALDH1A1RAB9ATSHRL3MBTL1CASP3
SCHEMBL11504619 0.82 ALDH1A1 (0.60) ALDH1A1SMN1; SMN2GAARAB9ATSHR
SCHEMBL6047510 0.81 ALDH1A1 (0.56) ALDH1A1SMN1; SMN2GAARAB9ATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 202 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250198037-A1 GOLD ELECTROPLATING SOLUTION AND ITS USE FOR ELECTRODEPOSITING GOLD WITH AN AGED APPEARANCE Université de Franche-Comté (FR) 2025-06-19 US claimed
EP-4493743-A1 GOLD ELECTROPLATING SOLUTION AND ITS USE FOR ELECTRODEPOSITING GOLD WITH AN AGED APPEARANCE Université de Franche-Comté (FR) 2025-01-22 EP claimed
WO-2023174871-A1 GOLD ELECTROPLATING SOLUTION AND ITS USE FOR ELECTRODEPOSITING GOLD WITH AN AGED APPEARANCE Université de Franche-Comté (FR) 2023-09-21 WO claimed
EP-4245893-A1 GOLD ELECTROPLATING SOLUTION AND ITS USE FOR ELECTRODEPOSITING GOLD WITH AN AGED APPEARANCE Université de Franche-Comté (FR) 2023-09-20 EP claimed
US-7642344-B2 Methods and compositions for determining the sequence of nucleic acid molecules OPERON BIOTECHNOLOGIES, INC. (US) 2010-01-05 US claimed
EP-0992511-B1 Methods and compositions for determining the sequence of nucleic acid molecules OPERON BIOTECHNOLOGIES INC (US) 2009-03-11 EP claimed
US-20080009613-A1 Methods and compositions for determining the sequence of nucleic acid molecules OPERON BIOTECHNOLOGIES, INC. (US) 2008-01-10 US claimed
US-7247434-B2 Methods and compositions for determining the sequence of nucleic acid molecules OPERON BIOTECHNOLOGIES, INC. (US) 2007-07-24 US claimed
EP-0868535-B9 METHODS AND COMPOSITIONS FOR DETERMINING THE SEQUENCE OF NUCLEIC ACID MOLECULES QIAGEN GENOMICS INC (US) 2007-05-09 EP claimed
EP-0868535-B2 METHODS AND COMPOSITIONS FOR DETERMINING THE SEQUENCE OF NUCLEIC ACID MOLECULES QIAGEN GENOMICS INC (US) 2006-01-04 EP claimed
EP-0990047-A2 METHODS AND COMPOSITIONS FOR ANALYZING NUCLEIC ACID MOLECULES UTILIZING SIZING TECHNIQUES Rapigene, Inc. (US) 2000-04-05 EP claimed
US-6027890-A DETECTING LIGAND BINDING BY INCUBATING TAGGED MEMBERS WITH BIOLOGICAL SAMPLE, SEPARATING BOUND FROM UNBOUND MEMBERS, CLEAVING TAG, THEN DETECTING BY NON-FLUORESCENT SPECTROSCOPY OR POTENTIOMETRY RAPIGENE, INC. (US) 2000-02-22 US claimed
EP-0962464-A2 Methods and compositions for detecting binding of ligand pair using non-fluorescent label Rapigene, Inc. (US) 1999-12-08 EP claimed
WO-1999005319-A9 METHODS AND COMPOUNDS FOR ANALYZING NUCLEIC ACIDS BY MASS SPECTROMETRY RAPIGENE INC (US) 1999-06-17 WO claimed
WO-1999005319-A2 METHODS AND COMPOUNDS FOR ANALYZING NUCLEIC ACIDS BY MASS SPECTROMETRY RAPIGENE, INC. (US) 1999-02-04 WO claimed
EP-0868535-A2 METHODS AND COMPOSITIONS FOR DETERMINING THE SEQUENCE OF NUCLEIC ACID MOLECULES Rapigene, Inc. (US) 1998-10-07 EP claimed
EP-0850320-A2 METHODS AND COMPOSITIONS FOR DETECTING BINDING OF LIGAND PAIR USING NON-FLUORESCENT LABEL DARWIN MOLECULAR CORPORATION (US) 1998-07-01 EP claimed
WO-1997027331-A9 METHODS AND COMPOSITIONS FOR DETERMINING THE SEQUENCE OF NUCLEIC ACID MOLECULES 1997-10-09 WO claimed
WO-1997027331-A2 METHODS AND COMPOSITIONS FOR DETERMINING THE SEQUENCE OF NUCLEIC ACID MOLECULES RAPIGENE, INC. (US) 1997-07-31 WO claimed
WO-1997027327-A2 METHODS AND COMPOSITIONS FOR DETECTING BINDING OF LIGAND PAIR USING NON-FLUORESCENT LABEL RAPIGENE, INC. (US) 1997-07-31 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080009613-A1 Methods and compositions for determining the sequence of nucleic acid molecules CPSF6, RNMT, POLM ALDH1A1 3332/4885SMN1; SMN2 936/4885GAA 1616/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.